Development of a near-care diagnostic test for Lyme disease

莱姆病近护理诊断测试的开发

• 批准号: 549597-2020
• 负责人: Frampton, John
• 金额: $ 25.36万
• 依托单位: Dalhousie University
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=699977
• 关键词: Development; near; care; diagnostic; test

Lyme disease is the most common tick-borne illness in North America. New cases of Lyme disease are on the rise throughout Canada, which has prompted increased awareness of the disease and raised issues with the currently available tests used for diagnosis. The current tests rely on detection of antibodies found in the patients blood that are produced in response to bacteria that cause Lyme disease. Because these antibody responses develop over time and vary with degree of infection, the test can be problematic for diagnosing early infection, which may delay antibiotic therapy. Recently, there has been a push to identify additional non-antibody Lyme disease markers for use in diagnosis. This research will use a sensitive and powerful protein discovery approach to mine blood samples for new markers of Lyme disease. The proteins identified will be used to develop an improved test for detecting Lyme disease.

莱姆病是北美最常见的tick传播疾病。莱姆新病例 疾病在整个加拿大都在增加，这促使人们对 疾病并提出了用于诊断目前可用测试的问题。电流 测试依赖于在患者血液中发现的抗体的检测。 引起莱姆病的细菌。因为这些抗体反应会随着时间的流逝而发展 随着感染程度的变化，该测试对于诊断早期感染可能是有问题的， 这可能会延迟抗生素疗法。最近，一直在推动确定其他 非抗体莱姆病标记用于诊断。这项研究将使用敏感的 以及强大的蛋白质发现方法，用于开采莱姆新标记的血液样品 疾病。确定的蛋白质将用于开发改进的检测莱姆的测试 疾病。